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Abstract A library of 121 pseudopeptides was designed to
develop reversible inhibitors of trypanosomal enzymes (cruzain
from Trypanosoma cruzi and congopain from Trypanosoma
congolense). The peptides share the framework: Cha-X1-X2-Pro
(Cha = cyclohexyl-alanine, X1 and X2 were phenylalanyl ana-
logs), based on a previous report [Lecaille, F., Authie¤, E.,
Moreau, T., Serveau, C., Gauthier, F. and Lalmanach, G. (2001)
Eur. J. Biochem. 268, 2733^2741]. Five peptides containing a
nitro-substituted aromatic residue (Tyr/Phe) and one a 4-chloro-
phenylalanine at the X1 position, and 3-(2-naphthyl)-alanine,
homocyclohexylalanine or 3-nitro-tyrosine (3-NO2-Tyr) at the
X2 position, were selected. They inhibited congopain more
effectively than cruzain, except Cha-4-NO2-Phe-3-NO2-Tyr-Pro
which bound the two parasitic enzymes similarly. Among this
series, Cha-3-NO2-Tyr-HoCha-Pro and Cha-4-NO2-Phe-3-
NO2-Tyr-Pro are the most selective for congopain relative to
host cathepsins. No hydrolysis occurred upon prolonged incuba-
tion time with purified enzymes. In addition introduction of non-
proteogenic residues in the peptidyl backbone greatly enhanced
resistance to proteolysis by mammalian sera. ß 2001 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Lysosomal cathepsins B, L, S or K, which are implicated in
the regulation of a broad range of biological functions, are
attractive chemotherapeutic targets for cure of pathological
processes, including arthritis, osteoporosis, or cancer invasion
[1^3]. Related protozoan proteases also play crucial roles in
the life cycle of parasites which are the etiological agents of
American trypanosomiasis and sleeping sickness in Africa [4^
6]. Cruzain from Trypanosoma cruzi, the causative agent of
Chagas disease in South America, and congopain, its homol-
ogous enzyme in Trypanosoma congolense, which is responsi-
ble of nagana in African bovine domestic livestock, share a
high sequence identity and an enzymatic speci¢city closely
related to that of mammalian cathepsins B and L [7^11]. In-
activation of trypanosomal cysteine proteases (CPs) by pep-
tidyl inhibitors o¡ers a promising therapeutic pathway as re-
cently demonstrated in a mouse model [12]. The substrate
speci¢city of trypanosomal CPs, as that of their mammalian
counterparts, is primarily determined by P2/S2 interactions,
with a marked preference for aromatic residues such as Phe
at P2. However we have recently found that trypanosomal
enzymes can accommodate non-aromatic, unencoded cyclic
amino acids such as 3-cyclohexyl-alanine (Cha) at P2 [13].
We also found that congopain and cruzain, but not cathepsins
B and L, accommodate Pro at P2P [8].
Reversible, tight-binding CP inhibitors would be the ideal
drug target leads and considerable e¡ort has been expended in
optimizing interactions within the active site of CPs with nat-
ural amino acids. Some gave promising results when assayed
in vitro but they most often displayed only a poor activity in
tissue cultures, due to transport failure across cell membrane,
susceptibility to endogenous proteolysis, and low water solu-
bility [14,15]. Interactions with unencoded amino acids have
not been studied in so great details until now, though their
incorporation in the peptidyl backbone of small reversible
inhibitors could improve their half-life and stability [16]. To
reach this goal, a library of pseudopeptidylamides were pre-
pared by solid phase synthesis and their ability to inhibit CPs
was evaluated.
2. Materials and methods
Z-Phe-Arg-AMC (7-amino-4-methyl-coumarin hydrochloride) and
Z-Ala-Ala-Pro-Phe-AMC were purchased from Bachem Biochimie
(Voisins-le-Bretonneux, France). L-3-carboxy-trans-2,3-epoxypropion-
yl-leucylamido-(4-guanido)butane (E-64), DL-dithiothreitol (DTT) and
Igepal CA-630 were from Sigma-Aldrich (St Quentin le Fallavier,
France). All other reagents were of analytical grade. Fetal calf serum
was purchased from Eurobio (Les Ulis, France). Bradykinin was ob-
tained from Sigma-Aldrich.
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2.1. Enzymes
Cruzain (recombinant catalytic domain of cruzipain) was puri¢ed as
previously described [17]. Congopain from T. congolense was prepared
by a⁄nity chromatography from trypomastigote lysates [18]. Human
recombinant cathepsin L was a generous gift from Dr. John S. Mort
(Shriners Hospital for Children, Montreal, QC, Canada). Cathepsin B
was puri¢ed from rat liver [19]. Trypsin and chymotrypsin from bo-
vine pancreas were purchased from Roche Molecular Biochemicals
(Mannheim, Germany). Prior to kinetic measurements, enzymes
were activated in their respective assay bu¡er for 5 min at 37‡C:
0.1 M phosphate bu¡er pH 6.0, containing 6 mM DTT, 2 mM
EDTA, 0.01% Igepal CA-630 for cruzain and congopain and 0.1 M
phosphate bu¡er pH 6.0, containing 2 mM DTT, 1 mM EDTA,
0.01% Igepal CA-630 for cathepsins L and B. The enzyme active
site was titrated by E-64, using Z-Phe-Arg-AMC as substrate [20].
The bu¡ers for trypsin and chymotrypsin assays were 0.4 M Tris^
HCl, pH 8.0 and 50 mM HEPES, 50 mM NaCl, pH 7.4 respectively.
Trypsin was titrated as previously described [21], while chymotrypsin
was titrated by K1-antichymotrypsin using Z-Ala-Ala-Pro-Phe-AMC
as substrate [22].
2.2. Peptides synthesis
Unless otherwise stated, all Fmoc-protected amino acids were of the
L-con¢guration, and were purchased from Neosystem (Strasbourg,
France) or Advanced ChemTech Europe (Brussels, Belgium). N,NP-
Diisopropylethylamine (DIPEA), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tet-
ramethyluronium hexa£uorophosphate (HBTU) were obtained from
Novabiochem (FranceBiochem, France). 121 pseudopeptidyl tet-
ramers (for nomenclature and numbering see Table 1) were synthe-
sized by Fmoc solid phase chemistry on a automated solid phase
peptide multi-synthesizer (357 FBS model, Advanced ChemTech), us-
ing a (4-(2P,4P-dimethoxyphenyl-Fmoc-aminomethyl-phenoxyacetami-
do-norleucyl)-4 methylbenzhydrylamine) resin (10 Wmol equivalent
(eq.)) from Novabiochem. The ¢rst residue, proline (10 eq.) was added
in the presence of HBTU (10 eq.) and DIPEA (10 eq.) in N-methyl-2-
pyrrolidinone (NMP) (double coupling). Incorporation of Phe analogs
was also achieved by double coupling (Fmoc-amino acid: 4 eq.,
HBTU: 4 eq., DIPEA: 4 eq.) in NMP. After cleavage from the resin
using tri£uoroacetic acid (TFA), triisopropylsilane, H2O (46:1:1 v/v)
(2 h at room temperature), pseudopeptidylamides were precipitated by
ethylic ether, redissolved in the presence of DMF, and lyophilized
before storage. Their homogeneity was checked by analytical reversed
phase-high performance liquid chromatography (RP-HPLC) (Brown-
lee C18 OD 300 column), using a 30-min linear (0^60%) acetonitrile
gradient in 0.1% TFA. Eluted peaks, monitored at three wavelengths
(220, 255 and 280 nm) and analyzed by the Spectacle software (Ther-
mo Finnigan, Les Ulis, France), showed a purity grade s 95%. Syn-
thesis of peptides PB 8 and PB 11 was reported elsewhere [23].
2.3. Kinetic measurement
Cruzain (0.65 nM) was incubated with each of the 121 pseudopep-
tides (10 and 100 WM) in the activating bu¡er at 37‡C for 10 min (¢nal
volume/96-well microplate = 100 Wl). After addition of Z-Phe-Arg-
AMC (3.26 WM) the residual enzymatic activity was followed by mon-
itoring the £uorescence release (spectro-micro£uorimeter SpectraMax
Gemini, Bioproducts), running the software SoftMaxPro (Bioprod-
ucts). Wavelenghts of 350 nm for excitation and of 430 nm for emis-
sion were chosen to avoid £uorescence resonance energy transfer in-
terferences [24]. Peptides (100 WM) showing an apparent inhibition
over 50% were further retained. Cruzain (0.65 nM) was incubated
with inhibitory peptides (0^100 WM) for 10 min at 37‡C before adding
substrate Z-Phe-Arg-AMC (1^10 WM). Their Ki values were calcu-
lated by plotting 1/v against [I] according to [25] (triplicate experi-
ments). The Ki of peptides 72, 90, 110, 111, 115 and 116 towards
congopain (1 nM) was determined under the same experimental con-
ditions and their abilities to interact with cathepsin L (1 nM) and
cathepsin B (1.2 nM) were measured using benzyloxycarbonyl-Phe-
Arg-AMC (1^20 WM) as substrate.
2.4. Peptide stability
Peptide 110 (100 WM) was incubated with cruzain (1 nM) in its
activation bu¡er at 37‡C for 1 h (¢nal volume = 30 Wl). Two aliquots
were removed, one for measuring the residual enzymatic activity in
the presence of Z-Phe-Arg-AMC (5 WM) and the other was mixed
with ethanol (300 Wl) to inactivate the enzyme. After removal of the
precipitate, the supernatant containing the native peptide and/or its
proteolytic fragments was evaporated, redissolved in 0.1% TFA, and
chromatographed by RP-HPLC on a C18 OD 300 Brownlee column,
using a 30-min linear (0^60%) gradient of acetonitrile in 0.1% TFA at
a £ow rate of 0.5 ml/min. The elution pro¢les were analyzed by the
software Spectacle. This experimental procedure was repeated with
congopain, cathepsin L, cathepsin B, trypsin, and chymotrypsin in
their respective activity bu¡er. Similar experiments were also carried
out with peptides 72, 90, 111, 115 and 116. The resistance of Cha-4-
nitro-phenylalanine (4-NO2-Phe)-3-nitro-tyrosine (3-NO2-Tyr)-Pro
(100 WM) to endogenous proteolysis was checked after incubation at
37‡C for 1 h in rat plasma and fetal calf serum. Peptides PB 8 and PB
11 derived from the proregion of procathepsin B [23], or bradykinin
(¢nal concentration: 100 WM), were used as control. The same experi-
ments were done with peptides 72, 90, 111, 115 and 116.
3. Results and discussion
Based on previous reports [8,13], we have synthesized 121
tetrapeptides sharing the common structure Cha-X1-X2-Pro
(Table 1), where Cha and Pro occupied the putative P2 and
P2P positions respectively, X1 and X2 being Phe derivatives
(Fig. 1). Despite the presence of bulky hydrophobic residues,
all peptides of this series are water soluble at a concentration
of 10 mM. The ability of peptides to inhibit cruzain was
screened by monitoring the residual enzymatic activity to-
wards Z-Phe-Arg-AMC. Under our experimental conditions,
the £uorescence of the 7-amino-4-methyl-coumaryl group
Table 1
Sequences and numbering of 4-mer pseudopeptides sharing the common framework: Cha-X1-X2-Pro
X1 X2
D-Phe Phg Chg Cha Hof HoCha 4-Cl-Phe 3,4-dichloro-phenylalanine
(3,4-Cl2-Phe)
4-NO2-Phe 3-NO2-Tyr Nal2
D-Phe 1 2 3 4 5 6 37 38 39 40 41
Phg 7 8 9 10 11 12 42 43 44 45 46
Chg 13 14 15 16 17 18 47 48 49 50 51
Cha 19 20 21 22 23 24 52 53 54 55 56
Hof 25 26 27 28 29 30 57 58 59 60 61
HoCha 31 32 33 34 35 36 62 63 64 65 66
4-Cl-Phe 67 68 69 70 71 72 97 98 99 100 101
3,4-Cl2-Phe 73 74 75 76 77 78 102 103 104 105 106
4-NO2-Phe 79 80 81 82 83 84 107 108 109 110 111
3-NO2-Tyr 85 86 87 88 89 90 112 113 114 115 116
Nal2 91 92 93 94 95 96 117 118 119 120 121
The 121 tetramers were synthesized as peptidylamides. Peptides were constructed on the basis of a previous report [13].
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(Vex = 350 nm and Vem = 430 nm) was not a¡ected by peptide
concentration.
Six peptides of the series, i.e. Cha-4-chloro-phenylalanine
(4-Cl-Phe)-homocyclohexyl-alanine (HoCha)-Pro (#72), Cha-
3-NO2-Tyr-HoCha-Pro (#90), Cha-4-NO2-Phe-3-NO2-Tyr-
Pro (#110), Cha-4-NO2-Phe-3-(2-naphthyl)-alanine (Nal2)-
Pro (#111), Cha-3-NO2-Tyr-3-NO2-Tyr-Pro (#115), and
Cha-3-NO2-Tyr-Nal2-Pro (#116) inhibited cruzain over 50%
(Fig. 2). Compared to the £uorogenic substrate dansyl-Cha-
Arg-Ala-Pro-Trp which is hydrolyzed at the Arg-Ala bond
[13], no proteolytic fragment of the 4-mer peptides was gen-
erated upon incubation with cruzain as observed by RP-
HPLC (not shown), demonstrating that peptides interacted
as CP inhibitors, and not as substrates. At variance with pep-
tidyl vinyl sulfones, where the most potent has a homophenyl-
alanine (Hof) at P1 [26], peptides 25^30 and 57^61 that also
have a Hof residue at P1 poorly inhibited cruzain. This agrees
with recent structural data reporting that Hof is not essential
for interactions between cruzain and vinyl sulfones [27]. In-
troduction of a saturated carbon cycle (cyclohexyl-glycine
(Chg), Cha, or HoCha) led to a loss of inhibition, emphasiz-
ing the critical importance of aromaticity of the X1 side chain.
Cruzain preferentially accommodated nitro-substituted Phe or
Tyr residues at P1, which suggests that substitution of the
benzyl ring by an electronegative group favored binding to
the putative S1 subsite. In a previous report, Alves et al.
[28] observed that the presence of a positively charged deriv-
ative of Cha (4-aminomethyl-cyclohexyl-alanine) at P1 in the
series ortho-amino-benzoyl-Phe-X-Ser-Arg-Gln-N-(2,4-dini-
tro-phenyl)-ethylenediamine led to an e⁄cient competitive in-
hibitor of cruzain and cathepsin L. This apparent discrepancy
Fig. 1. Molecular structure of phenylalanyl analogs. For sake of
clarity, only the side chain is drawn. See abbreviations for the listed
code corresponding to Phe analogs.
Fig. 2. Inhibitory pro¢les of peptides 1^121 versus cruzain. All peptides of the series Cha-X1-X2-Pro were screened for their ability to inhibit
cruzain, as reported in Section 2. The residual enzymatic activity of cruzain was followed by monitoring the £uorescence release from Z-Phe-
Arg-AMC. Peptides showing an inhibition over 50% were further retained for kinetic analysis.
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is probably due to the broad speci¢city of the S1 subsite
[11,27]. Our data also indicated that HoCha, Nal2, and
3-NO2-Tyr bound quite well to the S1P subsite of cruzain
(peptides 72, 90, 110, 111, 115, 116), while (D)-Phe, phenyl-
glycine (Phg), and Chg are poorly accepted.
The Ki of the six selected peptides was determined accord-
ing to [25] (Table 2). Peptides were slightly more potent com-
petitive inhibitors of congopain than of cruzain, except Cha-4-
NO2-Phe-3-NO2-Tyr-Pro (compound 110) which bound the
two parasitic enzymes similarly. Cha-3-NO2-Tyr-HoCha-Pro
and Cha-4-NO2-Phe-3-NO2-Tyr-Pro are respectively the most
selective for congopain relative to cathepsin B and cathepsin
L. Peptide 110 was the weakest inhibitor of human cathepsins
L and B (Ki = 0.2 mM) due to the presence of a 3-NO2-Tyr at
X2, a 3-(2-naphthyl)-alanyl residue being preferred at that
position (peptide 111). Despite the inhibitory potential of
small competitive inhibitors of trypanosomal CPs remains
moderate [29], their Ki values compare to numerous low mo-
lecular weight competitive reversible inhibitors of thiol pro-
teases (see for review [14]). Compared to reversible cystatin-
derived inhibitors or propeptide-derived peptides [30,31], no
hydrolysis of these peptides was detected by RP-HPLC upon
prolonged incubation time (5 h) with cathepsins B and L,
congopain, and cruzain, or unrelated proteases used as con-
trol (trypsin and chymotrypsin). This suggests that resistance
of competitive pseudopeptidyl inhibitors towards their cog-
nate CPs could be partly achieved by use of Phe structural
analogs. At this stage, stability of the selected peptides was
estimated in rat plasma and fetal calf serum. Approximately
25% of Cha-4-NO2-Phe-3-NO2-Tyr-Pro was recovered after 1
h incubation (not shown), while control peptides including PB
11 (a competitive procathepsin B-derived inhibitor) [23] were
rapidly and fully metabolized by serum proteases. Similar in-
crease of half-life was observed with peptides 72, 90, 111, 115
and 116, as reported for irreversible inhibitors [16]. Even
though the a⁄nity of such reversible low molecular weight
inhibitors, containing unencoded amino acids in their peptide
framework, remains weak in part due to their short length,
their increased properties in terms of stability and resistance
to proteolysis are promising vis a vis development of new
inhibitory compounds of biological interest to control un-
wanted activity of CPs.
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